Telephone
61.2.9541.0411
Address
Unit 4 1 The Crescent Kingsgrove, New South Wales (NSW) 2208
Description
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. It manufactures and sells medical devices and pharmaceutical products. The firm operates through Technegas and Molecular Imaging segments. The Technegas segment supplies diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The company was founded in 1984 and is headquartered in Kingsgrove, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 1.15 - 3.15
Trade Value (12mth)
AU$12,064.00
1 week
-1%
1 month
-0.5%
YTD
67.93%
1 year
50.76%
All time high
3.45
EPS 3 yr Growth
67.500%
EBITDA Margin
-27.30%
Operating Cashflow
-$7m
Free Cash Flow Return
-15.10%
ROIC
-15.00%
Interest Coverage
-23.90
Quick Ratio
3.60
Shares on Issue (Fully Dilluted)
92m
HALO Sector
Healthcare
Next Company Report Date
21-Feb-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 March 23 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 March 23 |
Appendix 4G
×
Appendix 4G |
31 March 22 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 March 22 |
Appendix 4G
×
Appendix 4G |
31 March 20 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 March 15 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 March 14 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 November 22 |
Change of Director's Interest Notice - DAngus
×
Change of Director's Interest Notice - DAngus |
30 March 23 |
Technegas Enters Final Six Month USFDA Review Cycle
×
Technegas Enters Final Six Month USFDA Review Cycle |
30 March 21 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
29 November 22 |
Cyclopharm Receives $1.64m R&D Refund
×
Cyclopharm Receives $1.64m R&D Refund |
29 May 18 |
CYC 2018 AGM Presentation
×
CYC 2018 AGM Presentation |
29 March 21 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 March 19 |
Annual Report to shareholders
×
Annual Report to shareholders |
28 May 12 |
AGM Presentation Audio Broadcast
×
AGM Presentation Audio Broadcast |
28 March 17 |
CYC Annual Report to Shareholders
×
CYC Annual Report to Shareholders |
28 March 13 |
Annual Report to shareholders
×
Annual Report to shareholders |
28 August 17 |
Cyclopharm Limited 1H2017 Results Investor Presentation
×
Cyclopharm Limited 1H2017 Results Investor Presentation |
28 August 07 |
Half Year Presentation
×
Half Year Presentation |
27 September 22 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
27 September 22 |
CYC Board Changes
×
CYC Board Changes |
27 May 08 |
2008 AGM Presentation - Audio Broadcast
×
2008 AGM Presentation - Audio Broadcast |
27 March 12 |
Annual Report to shareholders
×
Annual Report to shareholders |
27 July 15 |
CYC Investor Presentation July 2015
×
CYC Investor Presentation July 2015 |
27 April 18 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
26 September 23 |
Cyclopharm Investor Update
×
Cyclopharm Investor Update |
26 September 23 |
Investor Presentation Correction
×
Investor Presentation Correction |
26 September 23 |
Investor Presentation Correction
×
Investor Presentation Correction |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.